Leqembi wins NMPA nod for once-monthly IV dosing in early Alzheimer’s patients
LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment
LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting
The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.
Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets are indicated for the treatment of human immunodeficiency virus infection in adults and pediatric patients weighing at least 25 kg
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
Subscribe To Our Newsletter & Stay Updated